Purinergic receptors regulate various processes including epithelial transport. There are several studies on P2 receptors in pancreatic ducts of various species, but relatively little is known about these receptors in human tissue. The aim of this study was to identify purinergic receptors in human pancreatic duct cell lines PANC-1 and CFPAC-1. Expression of P2 receptors was examined using RT-PCR and immunocytochemistry. Both cell lines, and also Capan-1 cells, express RNA transcripts for the following receptors: P2Y1, P2Y2, P2Y4, P2Y6, P2Y11-14 and P2X1, P2X2, P2X4, P2X5, P2X6 and P2X7. Using Fura-2 and single-cell imaging we tested effects of various nucleotide analogues on intracellular Ca 
Introduction
ATP signalling plays important roles in diverse processes as cell migration, immune defence, cell volume regulation, synaptic transmission and epithelial transport [1] [2] [3] [4] [5] . Various epithelia and exocrine glands e.g. airway, inner ear, gastrointestinal tract, liver, kidney, and pancreas, express purinergic receptors belonging to two families: P2Y and P2X [6, 7] . The P2Y receptor family comprises 7-transmembrane spanning G-protein coupled receptors and in epithelia stimulation by ATP/UTP leads to Ca [2] [3] [4] . The P2X receptor family form ligandgated cation channels when assembled in homo-or heteromers, and can in epithelia aid Ca 2+ influx [2, 5] . Rat pancreatic acini cells "secrete" ATP in response to acetylcholine, cholecystokinin, mechanical stimulation and changes in cell volume, but expression of functional P2 receptors on acini is heterogenous and sparse [8, 9] . In contrast, several studies have shown functional P2 receptor expression in pancreatic ducts from rat, guinea pig and dog preparations. For example, native isolated rat ducts seem to express a range of functional P2 receptors, P2Y2, P2Y4, P2X4, P2X7, and respond consistently to ATP stimulation with changes in pH i , membrane potential, intracellular Ca 2+ signalling and activation/inhibition of diverse ion-transporters and exchangers [9] [10] [11] . Molecular biological approaches (RT-PCR) indicate that rat ducts express P2Y2, P2Y4, P2X4, P2X7 [11] , and possibly also P2X1, P2Y1 and P2Y5 receptors [12] . Reports on cultured dog pancreatic duct cells show functional expression of P2Y2 and P2Y11 receptors, which regulate Cl -and K + channels [13] [14] [15] . Studies on guinea pig ducts indicated expression of P2Y2 receptors, which regulate secretion [16] . Furthermore, immunohistochemistry on rat pancreas shows expression of P2Y1 and P2Y2 receptors in ductal tissue [17, 18] . Above described studies indicate that in pancreas of several animal species autocrine and paracrine ATP signalling and stimulation of P2 receptors may be important for exocrine functions, such as secretion and tissue homeostasis [19] .
Regarding the human pancreas, there are several publications on human duct cell lines reporting effects of the nucleotides ATP/UTP on Cl signalling [20] [21] [22] [23] [24] . Exact identification of P2 receptors is important as some P2 receptors could support exocrine secretion (via stimulation of cAMP or Ca 2+ activated Cl -channels), while others could inhibit exocrine secretion (via inhibition of K + channels), yet others have long-term effects on tissue homeostasis [19] . P2 receptors may be of therapeutic value for improving pancreatic secretion, such as in patients suffering from cystic fibrosis. In respiratory epithelia of patients with cystic fibrosis, P2Y2 receptor agonist has been tested for its ability to rescue fluid secretion by activation of Ca 2+ -activated Cl -channels (see press releases denufosol tetrasodium made by Inspire). In addition, since other cells in pancreas also express P2 receptors which are therapeutic targets, e.g. improvement of insulin secretion of β-cells, it is important to fingerprint P2 receptors in human pancreatic tissue [19] . So far, only two studies have attempted to determine the molecular identity of P2 receptors in human pancreas. In one study the human duct cell line Capan-1 and  whole pancreas were analyzed using RT-PCR and the  following expression profile was suggested -P2Y1, P2Y2,  P2Y4, P2Y6, P2X1, P2X4 and P2X5 receptors, but no P2X6 or P2X7 receptors were found [25] . Using samples from whole human pancreas, Künzli and co-workers [26] showed P2Y1, P2Y2, P2Y6 and P2X7 receptor RNA, and P2Y2 and P2X7 receptors were also identified with western blot. Nevertheless, using immunohistochemistry, P2Y2 and P2X7 receptors were apparently not found in epithelial cells but in endocrine cells, stellate cells and immune cells [26, 27] . It seems then that the P2 receptor expression in human pancreatic duct cells is not yet settled, especially regarding the P2X receptors. Since these receptors may be involved in short-term as well as long-term effects, it is important to determine if they are present on human pancreatic duct epithelium.
The aim of our study was to identify molecular and functional P2 receptor expression in human pancreatic duct cell lines, PANC-1 (and Capan-1) and CFPAC-1. These cell lines are most commonly used for epithelial transport studies and since fresh human ducts are almost impossible to obtain for physiological studies, these cell lines serve as models for human pancreatic duct epithelium [19] . While the PANC-1 (and Capan-1) cells express functional cystic fibrosis transmembrane regulator, CFTR [20, 28, 29] , the CFPAC-1 cell line is derived from a cystic fibrosis patient with ΔF508 mutated CFTR [30] . Our experimental approach was to estimate functional expression and molecular identity of P2 receptors by means of single cell Ca 2+ imaging combined with simple pharmacological approaches, RT-PCR and immunocytochemistry.
Materials and Methods

Cell culture
Pancreatic cell lines were purchased from ATTC (Manassas, VA, USA). PANC-1 (ATTC, #CRL-1469) was grown in Dulbecco's Modified Eagles Medium (DMEM), CFPAC-1 (#CRL-1918) and Capan-1 (#HTB-79) were grown in Iscove's Modified DMEM (IMDM), respectively. Cell culture media contained Glutamax, 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 µg/ml streptomycin. Some cultures were serum starved with 0.5% FBS for 1-2 days). All cells were grown at 37°C in a humidified atmosphere with 5% CO 2 for 5-7 days until a confluent monolayer was formed. Cells from passage 14 to 53 were used in this study. Cells were grown in NUNC plastic dishes when used for RNA extraction. For fluorescence microscopy, cells were grown in glass bottom dishes (Willco Wells, Amsterdam, Netherlands) or optically transparent plastic dishes from Ibidi (Munich, Germany). All chemicals were purchased from Sigma unless otherwise stated.
Immunocytochemistry
The duct cell lines were cultured to confluence on optically transparent dishes or on coverslips. Samples were rinsed in phosphate buffered saline (PBS) and fixed in methanol at -20 o C for 5 min. Subsequently, cells were washed in PBS with 0.1% Triton and autofluorescence was blocked in 0.1 M Tris-glycine. After blocking in 3% BSA, preparations were incubated overnight at 4 o C with 1:50 to 1:100 dilutions of various primary antibodies for P2 receptors. The following antibodies were used: polyclonal anti-P2X4 receptor raised against residues 370-388 of rat receptor (Alomone, APR-002); polyclonal anti-P2X7 raised against residues 136-152 of mouse receptor (Alomone, APR-008F); polyclonal anti-P2X7 receptor raised against internal region of human receptor (Santa Cruz, L-20) and anti-P2Y2 receptor raised against human receptor C-terminus (Santa Cruz, C-20). Subsequently, samples were incubated with secondary antibodies (1:400) conjugated to Alexa488 or Alexa568, and with nuclear stain DAPI (1:400). In some samples cells were stained with primary antibody for acetylated α-tubulin (1:5000), in order to mark microtubule and primary cilia. Control samples were prepared without the primary or secondary antibodies. Fluorescence was examined using Leica TCS NT/SP CLSM. Images were analyzed using Leica CLSM software or MetaMorph 5.0 software (Universal Imaging Corporation, West Chester, PA, USA). In some experiments where the bath solution needed to be changed, cells were allowed to rest about 10 min before testing of agonists. Addition of blank probe (saline buffer) to the cells in the chamber was used to check for any disturbances prior to experimenting.
In each experiment 20-40 cells in the field of view were evaluated. Addition of agonists caused an immediate and transient rise in the Fura-2 ratio. The peak value of this rise was defined by the maximum ΔFura-2 ratio for an average of all ROI in one dish, i.e. one experiment. Following the transient peak, responses decreased to a "plateau-like phase", during which some cells oscillated and others did not. Note that if responses of all cells within each experiment were averaged, then the smooth plateau-like patterns would be more apparent. For simplicity and quantitative comparisons between experiments, we will refer to this phase as the plateau phase. The level of this plateau was determined by averaging ΔFura-2 ratio values for one minute following end of the peak. For every experiment, responses of 20-40 cells were used to calculate the average Δpeak and Δplateau values. Also the number of responding and oscillating or non-oscillating cells was determined. In some experiments we performed in situ calibration using 1 μM ionomycin permeabilization. Estimated resting [Ca 2+ ] i in single Cell Physiol Biochem 2008;22:157-168 P2 Receptors in Pancreatics Ducts duct cells was 50-100 nmol/l and it increased to the peak values of 400-500 nmol/l with ATP/UTP stimulations. These [Ca 2+ ] i were similar to those observed in rat pancreatic ducts [31] . For analysis, ANOVA or unpaired t-test were used, when comparing group of experiments or two set of experiments, respectively; n refers to the number of experiments in a series, means and SEM are given in tables and P<0.05 was considered statistical significant.
Reverse transcriptase polymerase chain reaction (RT-PCR)
PANC-1, CFPAC-1 and Capan-1 cells were grown as described above for 6-7 days in NUNC petri dishes until confluent and in some cultures FBS was decreased to 0.5% for 1-2 days. Total RNA was isolated with Total RNA Isolation Reagent from ABgene (Rockford, IL, USA) according to the manufacturer's instructions. As negative control for DNA contamination PCR with β-actin specific primers was performed. No DNA contamination was detected (data not shown). RT-PCR was performed with OneStep RT-PCR kit (Qiagen). The amplification parameters were as follows: one cycle at 50°C for 30 min and one cycle at 95°C for 15 min followed by 35-40 cycles at 95°C for 1 min, 55-60°C depending on the specific receptor subtype for 1 min, 72°C for 1 min and finally one cycle at 72°C for 10 min. Subsequently, all reactions were subjected to electrophoresis on 1.2% agarose gels. Table 1 show sequences of the 15 primers used and the expected fragment lengths for their respective transcripts are also listed. Primers were synthesized by MWG Biotech (Ebersberg, Germany) and TAG Copenhagen A/S (Copenhagen, Denmark) and designed using VectorNTI software. Identity of products was confirmed by sequencing (MWG Biotech, Ebersberg, Germany).
Results
PANC-1 and CFPAC-1 cells in culture
PANC-1 and CFPAC-1 form adherent epithelial monolayers when grown on glass or plastic and show polarization as demonstrated for example by occludin localization [32, 33] . Such preparation of these model cell lines are most often used for studying ion transport and signalling in human pancreas (Introduction), and were appropriate for our study that required single-cell resolution of Ca 2+ signals. PANC-1 cells, derived from epitheliod carcinoma, form a monolayer of heterogenous cells with tendency to grow on top of each other when confluent (Fig. 1A) . CFPAC-1 cells, derived from a patient with cystic fibrosis expressing deletion in Phe-508 in CFTR, appear homogenous and they form a dense monolayer interrupted by a few void spaces (Fig. 1B) . PANC-1 cells seem to have more epithelial-like cytoskeletal arrangement compared to CFPAC-1 cells [34] . In addition, both types of cells form primary cilia on the apical surface (Fig. 1A, B) , similar to rodent and human pancreatic ducts [34] . peak followed by a plateau phase that declined with time (Fig. 3A) . Some cells oscillated and some gave a smooth response in Ca 2+ signals. UTP (Fig. 3C ) evoked a more sustained Ca 2+ plateau phase and more pronounced oscillations in most cells. Figure 3B and D represents similar recordings from CFPAC-1 cells stimulated with 100 μM agonists. ATP (Fig. 3B) evoked Ca 2+ signals that were oscillating in synchrony in most cells. Similarly, UTP (Fig.  3D ) also evoked an oscillatory response followed by a declining plateau. The ATP analogue ATPγS is more resistant to breakdown by nucleotidases. When applied to PANC-1 or CFPAC-1 cells (Fig. 3E, F) , it evoked Ca 2+ signals characterized by high responsiveness and oscillations similar to those seen with ATP. Like with the other nucleotides, ATP and UTP, the ATPγS-elicited responses seem to fade over time, indicating that also P2 receptor desensitization rather than nucleotide hydrolysis was involved.
In the next series of experiments we tested the effect of BzATP, a reputed P2X7 receptor agonist. In PANC-1 cells BzATP (Fig. 4A) signal that quickly faded to baseline for all cells. In these concentrations (100 μM) BzATP had no detrimental effect, such as cell blebbing and lysis on either PANC-1 or CFPAC-1 cells.
In one series of experiments the effect of ivermectin (IVM) treatment prior to ATP stimulation was also investigated ( Fig. 4C and D signals. In both PANC-1 and CFPAC-1 cells IVM (10 μM) given prior to ATP (100 μM) significantly increased ΔFura-2 ratio for the plateau phase compared to the control (ATP only). There was a similar tendency with IVM effect in the experiments with 30 µM ATP, but not 1 μM ATP (Table 2  and 3) . Taken together, these results indicate that IVM can potentiate the P2X4 receptor activity in both cell lines.
In some experiments we removed extracellular Ca 2+ and stimulated PANC-1 and CFPAC-1 cells with ATP. Fig. 4E and F show relatively robust and oscillating responses to stimulus that were maintained in both cell lines. Table 2 (Table 2) , as also seen at the single cell level (Fig. 3 and 4) . It appeared that PANC-1 cells responded to increasing ATP concentrations (1, 10 and 100 μM in control series and with ivermectin) with increasing Ca 2+ signals indicated by the mean peak and mean plateau (ΔFura-2 ratios), although differences were not statistically significant, most likely due to cellular and P2 receptor heterogeneity (see below). UTP also evoked large changes in Fura-2 ratios. The number of oscillating cells increased with higher UTP concentrations, but interestingly, it seemed that the plateau efflux (see discussion). The BzATP (100 μM) plateau phase value was significantly lower than that evoked with ATP (100 μM). Overall in PANC-1 cells, at equimolar nucleotide concentrations, the apparent rank order for agonist potency as judged by the plateau and the peak responses was UTP ≥ ATP = ATPγS > BzATP. With regard to the responsiveness of PANC-1 cells, UTP (100 μM) and BzATP (100 μM) gave a lower percentage of responding cells compared to ATP (100 μM). PANC-1 cells also showed a rather large variation in the agonists' ability to evoke oscillatory responses -12% to 95% of the responding cells were oscillating, depending on the nucleotide concentration.
Compared to PANC-1 cells, CFPAC-1 cells were generally more responsive to nucleotide analogues and they oscillated more synchronously (Table 3 , Fig. 3) . All of the agonists tested evoked large peak ΔFura-2 ratios similar in magnitude, but the plateau responses differed. Interestingly, ATP in high concentration (100 μM) evoked significantly lower plateau than low concentration of ATP (30 μM). BzATP (100 μM) resulted in Ca 2+ signals with a clear peak response, but near absence of a plateau phase and lack of oscillations (also see Fig. 4 ). At equimolar concentrations, the apparent rank order for agonists was UTP ≥ ATP = ATPγS > BzATP as judged by the plateau and the peak responses. Except for BzATP, almost all cells responded to given agonists with oscillations. 
RNA expression of various purinoceptors in duct cell lines
The above mentioned Fura-2 experiments gave clear indications that PANC-1 and CFPAC-1 cells express functional purinergic receptors of both the P2X and P2Y families. These observations led us to use RT-PCR analysis in order to further clarify the P2 receptor profile. Primers for detection of all the known P2 receptors were designed and RT-PCR was carried out on total RNA isolated from PANC-1, CFPAC-1 and also Capan-1 cells. All the P2Y receptors tested, i.e. P2Y1, 2, 4, 6, 11-14 turned out with cDNA transcripts of the expected size (Fig. 5A, Table 1) . Regarding the P2X receptors tested, not all showed positive results. P2X3 receptors could not be identified in the given cell lines (results not shown). For PANC-1 and CFPAC-1 cells P2X1, P2X2, P2X4, P2X5, P2X6 and P2X7 transcripts of expected size were detected (Fig. 5B, Table 1 ). The P2X7 primer set I gave the expected fragment of 334 kb and unspecific band of 400 bp. The P2X7 primer set II gave expected fragment length of 410 bp. In addition to RT-PCR analysis on PANC-1 and CFPAC-1 cells, we also used another human duct cell line Capan-1 and found P2 receptor expression similar to the other two cell lines (Fig. 5A and B) . The identity of mRNA for the most controversial P2 receptors, including P2X4 and P2X7 was confirmed by sequencing.
Localization of P2 receptors
Some key P2 receptors were also localized in duct cell lines and results are shown in Fig. 6 . Immunofluores- Table  1 ). Representative gels for at least three independent determinations. cence ascribed to the P2X4 receptor was detected in intracellular vesicles within both PANC-1 and CFPAC-1 cells (Fig. 6A and B) . In some PANC-1 cells it seems that also the plasma membrane was labeled. One P2X7 antibody (Alomone) showed predominant intracellular localization in CFPAC-1 cells and PANC-1 cells and some plasma membrane marking in top-growing PANC-1 cells (Fig. 6C and D) . Another P2X7 antibody (Santa Cruz) marked CFPAC-1 cells more sparingly, except for a few cells that showed intense vesicular staining (Fig. 6F) . In contrast, PANC-1 cells showed intense intracellular and plasma membrane staining (Fig. 6E) . P2Y2 antibody also localized intracellularly in both cell lines and in CFPAC-1 cells again occasionally a few cells showed marked staining in intracellular vesicles (Fig. 6G and H) .
Discussion
This is the first detailed molecular, immunocytochemical and functional analysis of purinergic receptor expression in human pancreatic duct cell lines, based on cell lines commonly used for ion-transport studies. Our Fura-2 experiments and expression at the mRNA and protein levels show that PANC-1 and CFPAC-1 (and Capan-1) human pancreatic duct cells express a number of functional purinergic receptor subtypes from both the P2Y and P2X families.
Fura-2 measurements on PANC-1 and CFPAC-1 cells gave different Ca responses. This potency range is similar to our earlier observations on rat pancreatic ducts [11, 35] . Interestingly, in PANC-1 cells maximal concentrations of UTP evoked lower plateau Ca 2+ signal than submaximal concentrations of UTP. In case of CFPAC-1 cells, similar phenomenon was observed with high concentrations of ATP (Table 2 and 3) . These effects may be due to receptor-specific stimulation of Ca Regarding the individual P2 receptor types, we draw the following conclusions from our Fura-2 studies. In PANC-1 and CFPAC-1 cells, addition of ATP, UTP or ATPγS evoked a transient Ca 2+ signal followed by a sustained plateau phase above the baseline level. Since UTP evokes large Ca 2+ responses in both cell lines, it is very likely that P2Y receptors (especially P2Y2 and P2Y4) are functionally expressed. In fact, the P2Y4 receptor was cloned from the human pancreas, although the receptor localization was unknown then [36] . Sensitivity to ATPγS may indicate presence of P2Y11 or P2Y1 and P2Y2 receptors [6] . The ATP analogue, BzATP, is characterized by its ability to activate Ca 2+ signals mainly from P2X7, but it may also stimulate other receptors such as P2X1, P2X3 and P2Y11 [5, 6] The anti-parasitic agent ivermectin (IVM) has been shown to augment Ca 2+ currents through ATP activated P2X4 receptor channels. IVM does not directly activate P2X4, but only has a modulating action, and it does not modulate P2X2, P2X3 or P2X7 receptors [37, 38] . In our present study we found that IVM (10 μM), added before stimulation with ATP (100 μM), significantly increased the plateau Ca 2+ response compared to ATP alone. Therefore, the functional data with IVM indicate that both PANC-1 and CFPAC-1 cells express functional P2X4 receptors. This is supported by our RT-PCR and immunolocalization data. Present data are then in agreement with the report on functional and molecular P2X4 receptor expression in rat duct cells [11] ; and the RNA expression profile in Capan-1 human duct cell line [25] .
In terms of individual cell Ca PANC-1 cells are more heterogeneous in cell size, form and monolayer appearance and cell-cell contact (Fig. 1) . Correspondingly, number of responding cells and oscillating Ca 2+ signals were more variable in PANC-1 cells. Most likely, the heterogeneous phenotype also manifests itself in P2 receptor expression. Naturally, this phenomenon will arise in experiments carried out on single cell level, such as in this study, compared to whole organ/ whole tissue level studies. Similar heterogeneity was also recently reported regarding expression of adenosine receptors in PANC-1 and CFPAC-1 cells [39] . Another example of functional P2 receptor heterogeneity was also observed in rat pancreatic acini and in parotid acini [2, 40, 41] .
One notable observation was that the Ca influx through P2X receptors is not involved (Fig. 3) . Similar Ca 2+ oscillations in response to ATP and UTP have been reported for rat pancreatic duct cells [39] and dog pancreatic duct cells [15] . Indeed oscillatory Ca 2+ responses have been observed for a number of different cells and with various agonists [42] , particularly in rat pancreatic acini where frequency and intensity depend on agonist [43] [44] [45] . It is proposed that such oscillations arise from interrelated Ca 2+ release from different Ca 2+ stores: InsP3-, cADPriboseand NAADP-sensitive stores [42, 46] . The alternative theory to the store model is that oscillations reflect local fluctuations in ATP hydrolysis, synthesis and release, as for example proposed for the Ca 2+ wave propagations in astrocytes [47, 48] . Such model appears unlikely in duct cells, as we observed oscillations with supposedly nondegradable agonist ATPγS. In addition, it is not likely that these effects are due to adenosine receptors, as in these pancreatic duct cells lines adenosine evokes very sparse Ca 2+ signals with different pattern compared to nucleotides [39] .
In order to determine the molecular identity of P2 receptors in duct cell lines RT-PCR analysis was performed on total RNA extracted from PANC-1 and CFPAC-1 cells. The data showed that both PANC-1 and CFPAC-1 cells expressed transcripts for P2Y1, P2Y2, P2Y4, P2Y6, P2Y11-14 and P2X1, P2X2, P2X4, P2X5, P2X6 and P2X7 receptors. Also analysis on Capan-1 cells shows the same P2 receptor signature. Although there is some disagreement about certain P2X receptors (see below), these results are overall in accordance with a recent study on one human pancreatic duct line, i.e. Capan-1 cells that were also found to expres P2Y1, P2Y2, P2Y4 and P2Y6 receptors [25] . In addition to the studies mentioned above, the present study shows transcripts for P2X2, P2X6 and P2X7 receptors and also for P2Y11-14 receptors. The P2Y12-P2Y13 receptors may not have been detected in our functional studies due to their coupling to cAMP signalling rather than Ca 2+ signalling. Nevertheless, the function of these receptors in regulation of ion transport should be considered. Furthermore, the role of the P2Y14 receptor, which is UDP-glucose receptor expressed in cells of the nervous system, is unexplored in pancreas.
Present immunocytochemical experiments also support our RT-PCR and functional data regarding P2Y2 and P2X4 and P2X7 receptors, although one should take specificity and receptor localization with reservation. We show expression of P2Y2 receptor in both PANC-1 and CFPAC-1 cells, and a few CFPAC-1 cells showed marked accumulation of fluorescence (Fig. 6 ). The data with P2Y2 receptor then agrees with immunocytochemistry data on rat pancreatic ducts [17, 18] . Until now, P2X4 and P2X7 receptors were not detected in rat or human pancreatic duct material [18, 26] . Present study shows P2X4 receptor immunofluorescence in both cell lines ( Fig. 6A and B) . Presumed receptor localization to intracellular vesicles has also been observed in a number of preparations which used antibodies and recombinant receptor expression [18, 49, 50] . Guo and coworkers [49] found that P2X4 receptors, which undergo rapid endocytosis, reside in intracellular compartments in HEK293 cells and these compartments also mark with lysosomal markers. Apparently, lysosomal versus plasma membrane marking can be affected by method of fixation. Two different antibodies for the P2X7 receptor used in the present study showed similar reaction in PANC-1 cells (Fig. 6E  and G) . In CFPAC-1 cells, however, much fewer cells were showing reaction with Santa Cruz P2X7 antibody. Again the marked punctuate intracellular localization of receptor compared to weaker plasma membrane expression agrees with other studies using antibodies and recombinant receptor expression [18, 49, 51] , and some localization agrees with endoplasmatic reticulum [49] .
Notably, until now evidence for the P2X7 and also P2X4 receptors was still not settled for human pancreas. Using whole human pancreas Künzli and co-workers [26, 27] reported P2X7 mRNA and protein, and immunohistochemistry showed P2X7 receptors in islet cells, immunoreactive cells and stellate cells, but apparently not on duct or acinar cells. Similar immunohistochemical localization was seen in another study on rat pancreas [17, 18] . Also Szücs and co-workers failed to detect P2X7 in Capan-1 cells (human duct cell line) and in the normal human pancreas RNA control reaction [25] . Nevertheless, two other groups [11, 12] have molecularly and functionally identified P2X4 and P2X7 receptors in rat pancreatic ducts, Thus, it seemed unlikely that these receptors should not be expressed in human pancreas. Therefore, in the present study we used several P2X7 primer sets, some also used for P2X4 and P2X7 detection in human parotid acini [52] , sequenced the products, and we show clearly that PANC-1, CFPAC-1 and Capan-1 all contain transcripts for P2X4 and P2X7 receptors. We also detected P2X4 and P2X7 receptors by immunofluorescence (see above). Most importantly, these molecular data are supported by our functional data, where we studied effects of BzATP and ivermectin on Ca 2+ signals, and conclude that human duct cells have similar functional P2X4 and P2X7 receptors. Interestingly, both types of receptors are also detected in human parotid acini and other salivary glands [2, 52] .
In conclusion, our functional and molecular data on P2 receptor expression in human pancreatic cell lines PANC-1 and CFPAC-1 show that they express a number of P2Y and P2X receptors. They express P2Y2 receptors, but also other P2Y receptors that may regulate ion and fluid transport. Most notably, human ducts express P2X4 and P2X7 receptors, which may have short-and longterm effects. The exact polarity of receptors and target proteins they affect, such as Cl -versus K + channels, will require more refined preparation of human pancreatic ducts. Nevertheless, similar to rat pancreas, one would expect that in human pancreas, ductal P2 receptors participate in modulation of fluid transport and possibly also in tissue homeostasis
